Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can routine testing catch Cisplatin's toll on hearing and balance?

NCT ID NCT06929468

Knowledge-focused Sponsor: Simon Jäger Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

This observational study follows people with head and neck squamous cell carcinoma who receive cisplatin-based chemoradiotherapy, comparing them with patients who receive radiotherapy alone. Participants undergo standardized hearing, tinnitus, and balance tests before, during, and after treatment. Researchers aim to measure how often inner ear damage occurs and to find practical ways to screen for and monitor it. Optional genetic testing looks for genes that may make some people more vulnerable to cisplatin-related hearing loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study identifies reliable early signs of inner ear damage, doctors could screen and monitor patients more closely and adjust treatment to protect hearing and balance.
What could go wrong
This is an observational study with a modest number of participants, so it can show patterns but cannot prove cause and effect. Findings may not apply to all treatment regimens or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with head and neck squamous cell carcinoma receiving treatment with cisplatin chemoradiotherapy or only radiotherapy at Klinikum Nuremberg in Nuremberg, Germany.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of head and neck squamous cell carcinoma * Cisplatin-based chemoradiotherapy (monotherapy or combination-therapy, adjuvant or neo-adjuvant) or only radiotherapy (control group) * Age 18 to 85 years * Signed agreement and willingness to participate in the study and adhere to the study protocol Exclusion Criteria: * Severe hearing impairment (WHO grade 3 or 4, corresponding to an audiometric ISO value of ≥61 dB in the better ear at frequencies of 500, 1000, 2000 and 4000 Hz) * Self-reported tinnitus or vestibular dysfunction in the last 3 months (only lead to exclusion of the corresponding secondary objectives, not to complete exclusion from the study) * Current cochlear implant * Concurrent treatment with loop diuretics (e.g. furosemide), aminoglycoside antibiotics or other known ototoxic substances in the last three months * Acute psychosis or serious psychiatric illness * Addiction disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cisplatin ototoxicity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Deafness Dizziness drug-induced hearing loss head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma hearing loss disorder Hearing Loss, Sensorineural Ototoxicity platinum-induced ototoxicity sensorineural hearing loss disorder Squamous Cell Carcinoma of Head and Neck toxic labyrinthitis vestibular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cisplatin ototoxicity Cisplatin-induced hearing loss Deafness Dizzyness Head and neck cancer Hearing loss Inner ear hearing loss Ototoxic hearing loss Ototoxicity, drug-induced Squamous cell carcinoma of the head and neck Vestibular disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Klinikum Nuremberg

    RECRUITING

    Nuremberg, Bavaria, 90419, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.